CKM
Creatine kinase M-type
Also known as: CKMM, KCRM_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P06732
- Gene
- CKM
- Ensembl
- ENSG00000104879
- Chromosome
- 19
- Canonical length
- 381 aa
- Protein class
- Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
OverviewNCBI Gene
The protein encoded by this gene is a cytoplasmic enzyme involved in energy homeostasis and is an important serum marker for myocardial infarction. The encoded protein reversibly catalyzes the transfer of phosphate between ATP and various phosphogens such as creatine phosphate. It acts as a homodimer in striated muscle as well as in other tissues, and as a heterodimer with a similar brain isozyme in heart. The encoded protein is a member of the ATP:guanido phosphotransferase protein family. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
381 residues, UniProt reviewed canonical sequence.
>P06732|CKM
1 MPFGNTHNKF KLNYKPEEEY PDLSKHNNHM AKVLTLELYK KLRDKETPSG FTVDDVIQTG
61 VDNPGHPFIM TVGCVAGDEE SYEVFKELFD PIISDRHGGY KPTDKHKTDL NHENLKGGDD
121 LDPNYVLSSR VRTGRSIKGY TLPPHCSRGE RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT
181 EKEQQQLIDD HFLFDKPVSP LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLRVISM
241 EKGGNMKEVF RRFCVGLQKI EEIFKKAGHP FMWNQHLGYV LTCPSNLGTG LRGGVHVKLA
301 HLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GSVFDVSNAD RLGSSEVEQV QLVVDGVKLM
361 VEMEKKLEKG QSIDDMIPAQ KLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CKM can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.22
- Highest tissue expression
- 68,909 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 68,909 nTPM
- tongue: 24,326 nTPM
- heart muscle: 4,664 nTPM
- esophagus: 484 nTPM
- salivary gland: 342 nTPM
- prostate: 126 nTPM
Single-cell type
- thymic myoid cells: 1,948 nCPM
- myonuclei: 774 nCPM
- parietal cells: 196 nCPM
- late spermatids: 102 nCPM
- cardiomyocytes: 70 nCPM
- myosatellite cells: 65 nCPM
Immune cell
- classical monocyte: 0.7 nTPM
- myeloid DC: 0.5 nTPM
- intermediate monocyte: 0.3 nTPM
- total PBMC: 0.2 nTPM
- basophil: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- basal ganglia: 1.8 nTPM
- cerebral cortex: 1.7 nTPM
- cerebellum: 1.6 nTPM
- medulla oblongata: 1.5 nTPM
- pons: 1.5 nTPM
- white matter: 1.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CKM.
Disease | ImmuneIEDB
Conditions an epitope on CKM was assayed in.
- multiple sclerosis B cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.79
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.66
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- ATP:guanido phosphotransferase
- Glutamine synthetase/guanido kinase, catalytic domain
- ATP:guanido phosphotransferase, N-terminal
- ATP:guanido phosphotransferase, catalytic domain
- ATP:guanido phosphotransferase active site
- ATP:guanido phosphotransferase, N-terminal domain superfamily
- ATP:guanido phosphotransferase, C-terminal catalytic domain
- ATP:guanido phosphotransferase, N-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CKM in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CKM as an antibody target. Whether an autoantibody or antibody against CKM could matter depends on whether native CKM is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CKM is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CKM as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...